|
1
|
El-Serag HB, Christie IC, Puenpatom A,
Castillo D, Kanwal F and Kramer JR: The effects of sustained
virological response to direct-acting anti-viral therapy on the
risk of extrahepatic manifestations of hepatitis C infection.
Aliment Pharmacol Ther. 49:1442–1447. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fattovich G, Stroffolini T, Zagni I and
Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk
factors. Gastroenterology. 127 (5 Suppl 1):S35–S50. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pawlotsky JM, Feld JJ, Zeuzem S and
Hoofnagle JH: From non-A, non-B hepatitis to hepatitis C virus
cure. J Hepatol. 62 (Suppl 1):S87–S99. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Drafting Committee for Hepatitis
Management Guidelines the Japan Society of Hepatology. JSH
Guidelines for the management of hepatitis C virus infection: A
2014 update for genotype 1. Hepatol Res. 44 (Suppl S1):S59–S70.
2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Peveling-Oberhag J, Arcaini L, Hansmann ML
and Zeuzem S: Hepatitis C-associated B-cell non-Hodgkin lymphomas.
Epidemiology, molecular signature and clinical management. J
Hepatol. 59:169–177. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
de Sanjose S, Benavente Y, Vajdic CM,
Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y,
Franceschi S, et al: Hepatitis C and non-Hodgkin lymphoma among
4784 cases and 6269 controls from the International Lymphoma
Epidemiology Consortium. Clin Gastroenterol Hepatol. 6:451–458.
2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Carloni G, Fioretti D, Rinaldi M and
Ponzetto A: Heterogeneity and coexistence of oncogenic mechanisms
involved in HCV-associated B-cell lymphomas. Crit Rev Oncol
Hematol. 138:156–171. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dang H, Yeo YH, Yasuda S, Huang CF, Iio E,
Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, et al: Cure with
interferon free DAA is associated with increased survival in
patients with HCV related HCC from both East and West. Hepatology.
71:1910–1922. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ikeda K, Kawamura Y, Kobayashi M, Kominami
Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, et
al: Direct-acting antivirals decreased tumor recurrence after
initial treatment of hepatitis C virus-related hepatocellular
carcinoma. Dig Dis Sci. 62:2932–2942. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Imai K, Takai K, Hanai T, Suetsugu A,
Shiraki M and Shimizu M: Sustained virological response by
direct-acting antivirals reduces the recurrence risk of hepatitis
C-related hepatocellular carcinoma after curative treatment. Mol
Clin Oncol. 12:111–116. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Michot JM, Canioni D, Driss H, Alric L,
Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, et
al: Antiviral therapy is associated with a better survival in
patients with hepatitis C virus and B-cell non-Hodgkin lymphomas,
ANRS HC-13 lympho-C study. Am J Hematol. 90:197–203.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Arcaini L, Besson C, Frigeni M, Fontaine
H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V,
Peveling-Oberhag J, et al: Interferon-free antiviral treatment in
B-cell lymphoproliferative disorders associated with hepatitis C
virus infection. Blood. 128:2527–2532. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nicolini LA, Zappulo E, Viscoli C and
Mikulska M: Management of chronic viral hepatitis in the
hematological patient. Expert Rev Anti Infect Ther. 16:227–241.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rossotti R, Travi G, Pazzi A, Baiguera C,
Morra E and Puoti M: Rapid clearance of HCV-related splenic
marginal zone lymphoma under an interferon-free, NS3/NS4A
inhibitor-based treatment. A case report. J Hepatol. 62:234–237.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Merli M, Carli G, Arcaini L and Visco C:
Antiviral therapy of hepatitis C as curative treatment of indolent
B-cell lymphoma. World J Gastroenterol. 22:8447–8458.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Arcaini L, Rossi D and Paulli M: Splenic
marginal zone lymphoma: From genetics to management. Blood.
127:2072–2081. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hirose S, Yamaji Y, Tsuruya K, Ogawa Y,
Miyaoka M and Kagawa T: Rapid regression of B-cell non-Hodgkin's
lymphoma after eradication of hepatitis C virus by direct antiviral
agents. Case Rep Gastroenterol. 13:336–341. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Carrier P, Jaccard A, Jacques J, Tabouret
T, Debette-Gratien M, Abraham J, Mesturoux L, Marquet P, Alain S,
Sautereau D, et al: HCV-associated B-cell non-Hodgkin lymphomas and
new direct antiviral agents. Liver Int. 35:2222–2227.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Persico M, Aglitti A, Caruso R, De Renzo
A, Selleri C, Califano C, Abenavoli L, Federico A and Masarone M:
Efficacy and safety of new direct antiviral agents in hepatitis C
virus-infected patients with diffuse large B-cell non-Hodgkin's
lymphoma. Hepatology. 67:48–55. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Merli M, Frigeni M, Gotti M, Grossi P,
Bruno R, Passamonti F and Arcaini L: Direct-acting antivirals
during or after immunochemotherapy in hepatitis C virus-positive
diffuse large B-cell lymphomas. Hepatology. 66:1341–1343.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zignego AL, Ramos-Casals M, Ferri C,
Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC,
Comarmond C, Gragnani L, et al: International therapeutic
guidelines for patients with HCV-related extrahepatic disorders A
multidisciplinary expert statement. Autoimmun Rev. 16:523–541.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lin RJ, Moskovits T, Diefenbach CS and
Hymes KB: Development of highly aggressive mantle cell lymphoma
after sofosbuvir treatment of hepatitis C. Blood Cancer J.
6(e402)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ohzato Y, Murakami M, Shimizu J, Koga C,
Marukawa D, Yoshida Y, Yasuyama A, Matsumura T, Takada A, Kameda C,
et al: A case report of inguinal malignant lymphoma after surgery
for hepatocellular carcinoma. Gan To Kagaku Ryoho. 44:1638–1640.
2017.PubMed/NCBI(In Japanese).
|
|
24
|
Rodríguez de Santiago E, Velázquez Kennedy
K, García González M, Gea Rodríguez F, Téllez Villajos L, Tavío
Hernández E and Albillos A: HCV-positive lymphoma after sustained
virological response with direct-acting antiviral agents: The game
is not over after HCV eradication. J Viral Hepat. 25:614–615.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Andrade XA, Paz LH, Nassar M, Oramas DM,
Fuentes HE, Kovarik P, Mishra S and Singh A: Primary liver diffuse
large B-cell lymphoma following complete response for hepatitis C
infection after direct antiviral therapy. Acta Haematol. 139:77–80.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Iwane K, Kayahara T, Takabatake H,
Morimoto Y, Iseki A, Mizuno M and Notohara K: Recurrence of
malignant lymphoma immediately after treatment for hepatitis C
virus using direct-acting antivirals. Nihon Shokakibyo Gakkai
Zasshi. 116:177–183. 2019.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
27
|
Gisbert JP, García-Buey L, Pajares JM and
Moreno-Otero R: Prevalence of hepatitis C virus infection in B-cell
non-Hodgkin's lymphoma: Systematic review and meta-analysis.
Gastroenterology. 125:1723–1732. 2003.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Matsuo K, Kusano A, Sugumar A, Nakamura S,
Tajima K and Mueller NE: Effect of hepatitis C virus infection on
the risk of non-Hodgkin's lymphoma: A meta-analysis of
epidemiological studies. Cancer Sci. 95:745–752. 2004.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rosa D, Saletti G, De Gregorio E, Zorat F,
Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G and
Abrignani S: Activation of naive B lymphocytes via CD81, a
pathogenetic mechanism for hepatitis C virus-associated B
lymphocyte disorders. Proc Natl Acad Sci USA. 102:18544–18549.
2005.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Carter RH and Fearon DT: CD19: Lowering
the threshold for antigen receptor stimulation of B lymphocytes.
Science. 256:105–107. 1992.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Machida K, Cheng KT, Sung VM, Shimodaira
S, Lindsay KL, Levine AM, Lai MY and Lai MM: Hepatitis C virus
induces a mutator phenotype: Enhanced mutations of immunoglobulin
and protooncogenes. Proc Natl Acad Sci USA. 101:4262–4267.
2004.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Khoury J, Nassar G, Kramsky R and Saadi T:
Extrahepatic malignancies after treatment with direct antiviral
agents for chronic HCV infection. J Gastrointest Cancer.
51:584–590. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ioannou GN, Green PK, Berry K and Graf SA:
Eradication of hepatitis C virus is associated with reduction in
hematologic malignancies: Major differences between interferon and
direct-acting antivirals. Hepatol Commun. 3:1124–1136.
2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Langhans B, Nischalke HD, Krämer B, Hausen
A, Dold L, van Heteren P, Hüneburg R, Nattermann J, Strassburg CP
and Spengler U: Increased peripheral CD4+ regulatory T
cells persist after successful direct-acting antiviral treatment of
chronic hepatitis C. J Hepatol. 66:888–896. 2017.PubMed/NCBI View Article : Google Scholar : (In Albanian,
English).
|
|
35
|
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE
and Ansell SM: Attenuation of CD8(+) T-cell function by
CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.
Cancer Res. 66:10145–10152. 2006.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Reig M, Boix L, Mariño Z, Torres F, Forns
X and Bruix J: Liver cancer emergence associated with antiviral
treatment: An immune surveillance failure? Semin Liver Dis.
37:109–118. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Villani R, Facciorusso A, Bellanti F,
Tamborra R, Piscazzi A, Landriscina M, Vendemiale G and Serviddio
G: DAAs rapidly reduce inflammation but increase serum VEGF level:
A rationale for tumor risk during anti-HCV treatment. PLoS One.
11(e0167934)2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Podar K and Anderson KC: The
pathophysiologic role of VEGF in hematologic malignancies:
Therapeutic implications. Blood. 105:1383–1395. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gratzinger D, Zhao S, Marinelli RJ, Kapp
AV, Tibshirani RJ, Hammer AS, Hamilton-Dutoit S and Natkunam Y:
Microvessel density and expression of vascular endothelial growth
factor and its receptors in diffuse large B-cell lymphoma subtypes.
Am J Pathol. 170:1362–1369. 2007.PubMed/NCBI View Article : Google Scholar
|
